A citation-based method for searching scientific literature

Kai Jiang, Yue Xu, Dandan Wang, Feng Chen, Zizhuo Tu, Jie Qian, Sheng Xu, Yixiang Xu, John Hwa, Jian Li, Hongcai Shang, Yaozu Xiang. Protein Cell 2022
Times Cited: 15







List of co-cited articles
172 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
53

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
46

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
227
40

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
986
40

Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia.
Yang Liu, Sanae Shoji-Kawata, Rhea M Sumpter, Yongjie Wei, Vanessa Ginet, Liying Zhang, Bruce Posner, Khoa A Tran, Douglas R Green, Ramnik J Xavier,[...]. Proc Natl Acad Sci U S A 2013
351
33

Upregulation of Rubicon promotes autosis during myocardial ischemia/reperfusion injury.
Jihoon Nah, Peiyong Zhai, Chun-Yang Huang, Álvaro F Fernández, Satvik Mareedu, Beth Levine, Junichi Sadoshima. J Clin Invest 2020
35
33

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
33

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
33

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
291
33

The Role of Autophagy in the Heart.
Sebastiano Sciarretta, Yasuhiro Maejima, Daniela Zablocki, Junichi Sadoshima. Annu Rev Physiol 2018
190
26

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. Cardiovasc Diabetol 2017
174
26


Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen. Diabetes Obes Metab 2018
126
26

Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Alana Aragón-Herrera, Sandra Feijóo-Bandín, Manuel Otero Santiago, Luis Barral, Manuel Campos-Toimil, José Gil-Longo, Thiago M Costa Pereira, Tomás García-Caballero, Santiago Rodríguez-Segade, Javier Rodríguez,[...]. Biochem Pharmacol 2019
53
26

TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity.
Chao-Yung Wang, Chun-Chi Chen, Mei-Hsiu Lin, Hui-Ting Su, Ming-Yun Ho, Jih-Kai Yeh, Ming-Lung Tsai, I-Chang Hsieh, Ming-Shien Wen. Biology (Basel) 2020
8
50

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Javad Habibi, Annayya R Aroor, James R Sowers, Guanghong Jia, Melvin R Hayden, Mona Garro, Brady Barron, Eric Mayoux, R Scott Rector, Adam Whaley-Connell,[...]. Cardiovasc Diabetol 2017
128
26

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
545
26

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells.
Chenke Xu, Wei Wang, Jin Zhong, Fan Lei, Naihan Xu, Yaou Zhang, Weidong Xie. Biochem Pharmacol 2018
69
26


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
26


SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li,[...]. Cardiovasc Diabetol 2019
151
20

Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy.
Yutaka Matsui, Hiromitsu Takagi, Xueping Qu, Maha Abdellatif, Hideyuki Sakoda, Tomoichiro Asano, Beth Levine, Junichi Sadoshima. Circ Res 2007
20

Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death.
Satoru Kobayashi, Paul Volden, Derek Timm, Kai Mao, Xianmin Xu, Qiangrong Liang. J Biol Chem 2010
182
20


Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.
Sayaka Maeda, Takanori Matsui, Masayoshi Takeuchi, Sho-ichi Yamagishi. Diabetes Metab Res Rev 2013
60
20

High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
Hiroyuki Umino, Kazuhiro Hasegawa, Hitoshi Minakuchi, Hirokazu Muraoka, Takahisa Kawaguchi, Takeshi Kanda, Hirobumi Tokuyama, Shu Wakino, Hiroshi Itoh. Sci Rep 2018
66
20

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
M J Davies, A Trujillo, U Vijapurkar, C V Damaraju, G Meininger. Diabetes Obes Metab 2015
78
20


Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Kristina Striepe, Agnes Jumar, Christian Ott, Marina V Karg, Markus P Schneider, Dennis Kannenkeril, Roland E Schmieder. Circulation 2017
68
20

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova,[...]. PLoS One 2014
162
20

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
378
20

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux,[...]. JACC Basic Transl Sci 2018
158
20

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
509
20


Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
Chintan N Koyani, Ioanna Plastira, Harald Sourij, Seth Hallström, Albrecht Schmidt, Peter P Rainer, Heiko Bugger, Saša Frank, Ernst Malle, Dirk von Lewinski. Pharmacol Res 2020
31
20

Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.
Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, Hiroki Teragawa, Yosuke Okada, Kosuke R Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Shigeru Toyoda,[...]. Diabetes Care 2019
27
20

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
16
20

Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
Valentina Spigoni, Federica Fantuzzi, Cecilia Carubbi, Giulia Pozzi, Elena Masselli, Giuliana Gobbi, Anna Solini, Riccardo C Bonadonna, Alessandra Dei Cas. Cardiovasc Diabetol 2020
24
20

Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
Masashi Mizuno, Atsushi Kuno, Toshiyuki Yano, Takayuki Miki, Hiroto Oshima, Tatsuya Sato, Kei Nakata, Yukishige Kimura, Masaya Tanno, Tetsuji Miura. Physiol Rep 2018
65
20

Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
Yu Jin Chung, Kyung Chan Park, Sergiy Tokar, Thomas R Eykyn, William Fuller, Davor Pavlovic, Pawel Swietach, Michael J Shattock. Cardiovasc Res 2021
33
20

Empagliflozin inhibits Na+ /H+ exchanger activity in human atrial cardiomyocytes.
Maximilian Trum, Johannes Riechel, Simon Lebek, Steffen Pabel, Samuel T Sossalla, Stephan Hirt, Michael Arzt, Lars S Maier, Stefan Wagner. ESC Heart Fail 2020
24
20

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.
Chang Myung Oh, Sungsoo Cho, Ji Yong Jang, Hyeongseok Kim, Sukyung Chun, Minkyung Choi, Sangkyu Park, Young Guk Ko. Korean Circ J 2019
28
13

Autophagy: cellular and molecular mechanisms.
Danielle Glick, Sandra Barth, Kay F Macleod. J Pathol 2010
13

Autophagy in Human Diseases.
Noboru Mizushima, Beth Levine. N Engl J Med 2020
165
13

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.
Ioanna Andreadou, Panagiotis Efentakis, Evangelos Balafas, Gabriele Togliatto, Constantinos H Davos, Aimilia Varela, Constantinos A Dimitriou, Panagiota-Efstathia Nikolaou, Eirini Maratou, Vaia Lambadiari,[...]. Front Physiol 2017
66
13


AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1.
Joungmok Kim, Mondira Kundu, Benoit Viollet, Kun-Liang Guan. Nat Cell Biol 2011
13


Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.
Lihe Lu, Weikang Wu, Jianyun Yan, Xiaohong Li, Huimin Yu, Xiyong Yu. Int J Cardiol 2009
127
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.